Sökning: "HIV-I"
Visar resultat 1 - 5 av 18 avhandlingar innehållade ordet HIV-I.
1. Primary HIV-1 infection : diagnostic, prognostic, and therapeutic aspects
Sammanfattning : Primary HIV-1 infection (PHI) is usually defined as a mononucleosis-like illness associated with seroconversion to HIV. In earlier studies using 1st generation antibody tests, the duration of the 'window period' from infection to detection of specific HIV-antibodies, could be 2 to 3 months, or longer. LÄS MER
2. Alphavirus vectors as recombinant vaccines
Sammanfattning : This thesis describes further developments of an expression system based on the alphavirus Semliki Forest virus (SFV), and its potential use as recombinant vaccine. The RNA genome of SFV contains a 3'open reading frame (ORF) encoding the structural proteins, and a 5' ORF coding for the viral replicase. LÄS MER
3. Studies of T cells in health and disease : receptor usage and cytokine expression
Sammanfattning : T Iymphocytes are crucial components for the initiation and maintenance of an immune response. To identify and characterize different T cells and their antigen specific receptors has important bearing for the understanding of underlying mechanisms in immunopathological processes and also to allow for the design of therapeutic therapies to be used for modulation of immune responses. LÄS MER
4. HIV-1 reverse transcriptase as a target in the development of specific enzyme inhibitors
Sammanfattning : Human immunodeficiency virus type I (HIV-I), which causes the acquired immunodeficiency syndrome (AIDS), begins its intracellular infection life cycle with reverse transcription of its plus-strand RNA genome into a double-stranded proviral DNA intermediate which is integrated into the host chromosome inducing a persistent infection. A virally encoded enzyme, reverse transcriptase (RT), carries out the reverse transcription process by performing all three enzymatic activities, i. LÄS MER
5. The metabolism of HIV RT inhibitors : biochemical and clinical studies
Sammanfattning : HIV infection is currently treated with a combination of nucleoside analogues and protease inhibitors. Nucleoside analogues inhibit HIV-1 reversed transcriptase (RT), a vital enzyme in the life cycle of HIV. Nucleoside analogues are phophorylated by host-cell enzymes to their respective triphosphate. LÄS MER